A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy

Administered By

Awarded By

Contributors

Start/End

  • September 1, 2016 - September 1, 2022